Even though a direct association or synergic effects of the SHP treatment beyond PTH control has not been reported with the combination of etelcalcetide and paricalcitol, the significant decrease of CRP appears to support the notion that the chronic inflammation state in HD patients could be improved. Here, CRP is linked to Huntington disease.